Feasibility study of alternate day oral therapy with TS-1 in patients with unresectable pancreatic cancer or biliry tract cancer

Not Applicable

• Conditions: pancreatic cancer or biliary tract cancer

• Registration Number: JPRN-UMIN000014805
• Lead Sponsor: Keio University School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-08-11
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Not provided

Exclusion Criteria

1)administration contraindication of TS-1 2)with clinically important infection 3)with sever heart failure 4)with interstitial pneumonia or pulmonary fibrosis 5)with sever complication(Intestinal paralysis, Ileus, uncontrollable diabetes mellitus, Renal failure, Liver failure etc) 6)massive ascites fluid or pleural effusion 7)repetitive blood infusion for gastrointestinal hemorrhage 8)with mental disorder receving treatment or needing treatment 9)administered Flucytosine, Phenytoin, Warfarin potassium 10)pregnant women or lactating women or women who like be pregnant and willing to get pregnant, men who want his partner to be pregnant 11)doctor's decision not to be registered to this study

Study & Design

• Study Type: Interventional
• Study Design: Not specified